Please assess the completion status of the following clinical trial:

Trial Title: Phase II Study of Lucanix™ in Patients With Stages II-IV Non-Small Cell Lung Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent~* 18 years~* Histologically confirmed non-curable NSCLC with an estimated total tumor burden volume of less than or equal to 125 cc, confirmed to be stage II, III, or IV.~* Must have completed or refused conventional therapy~* Performance status (ECOG) less than 2.~* Absolute granulocyte count greater than or equal to 1,500/mm3~* Platelet count greater than or equal to 100,000/mm3~* Total Bilirubin less than or equal to 2 mg/dL~* AST and ALT less than or equal to 2x Upper Limit of Normal~* Creatinine less than or equal to 1.5 mg/Dl~Exclusion Criteria:~* Concurrent systemic steroids greater than 2 mg prednisone/day~* Prior splenectomy~* Any surgery involving general anesthesia, chemotherapy, radiotherapy, steroid therapy or immunotherapy less than 4 weeks of study entry~* Brain metastases or meningeal lymphomatosis unless treated and stable for ≥ 2 months~* Known HIV positive~* Serious non-malignant disease (e.g., congestive heart failure, or active uncontrolled bacterial, viral, or fungal infections), or other conditions which, in the opinion of the investigator would compromise protocol objectives.~* Prior malignancy (excluding nonmelanoma carcinomas of the skin) unless in remission for greater than or equal to 2 years~* Treatment with an investigational drug within 30 days prior to study entry~* History of psychiatric disorder that would impede adherence to protocol~* Pregnant or nursing women or refusal to practice contraception if of reproductive potential

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lucanix (Type: EXPERIMENTAL): Patients will receive injections of Lucanix for each dose cohort.

Based on this trial design, predict the completion outcome and termination type (if applicable).